Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Synlogic Reports Third Quarter 2022 Financial Results and Provides Business Update

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease

Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

Synlogic Announces Second Quarter 2022 Conference Call and Webcast

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Synlogic Announces Appointment of General Counsel and Corporate Secretary